The estimated Net Worth of Bio Ventures Limited Partne... is at least $110 Million dollars as of 13 April 2020. Bio Partne owns over 120,000 units of Keros Therapeutics stock worth over $110,217,335 and over the last 5 years Bio sold KROS stock worth over $0.
Bio has made over 1 trades of the Keros Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Bio bought 120,000 units of KROS stock worth $1,920,000 on 13 April 2020.
The largest trade Bio's ever made was buying 120,000 units of Keros Therapeutics stock on 13 April 2020 worth over $1,920,000. On average, Bio trades about 120,000 units every 0 days since 2020. As of 13 April 2020 Bio still owns at least 2,013,102 units of Keros Therapeutics stock.
You can see the complete history of Bio Partne stock trades at the bottom of the page.
Over the last 5 years, insiders at Keros Therapeutics have traded over $50,765,607 worth of Keros Therapeutics stock and bought 2,504,088 units worth $46,191,339 . The most active insiders traders include Ran Nussbaum, Carl L Gordon und Tomer Kariv. On average, Keros Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of $3,312,649. The most recent stock trade was executed by Carl L Gordon on 13 August 2024, trading 250,000 units of KROS stock currently worth $11,002,500.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics executives and other stock owners filed with the SEC include: